Exploratory Study of Molecular Profile-Associated Evidence Guided Precision Therapy for Salivary Gland Cancer
Latest Information Update: 10 Jul 2024
Price :
$35 *
At a glance
- Drugs Bicalutamide (Primary) ; Leuprorelin (Primary) ; Pyrotinib (Primary)
- Indications Adenocarcinoma; Carcinoma; Salivary gland cancer
- Focus Therapeutic Use
- Acronyms MAPS
- 04 Jun 2024 Results of the efficacy and safety of pyrotinib, presented at the 60th Annual Meeting of the American Society of Clinical Oncology
- 25 Oct 2021 New trial record